What is the latest BROOKS stock price?
The latest stored price for BROOKS is Rs 64.56 as of 2026-11-03.
gimli
BROOKS stock AI analysis
BROOKS Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
BROOKS LAB LIMITED is a small-cap stock in Healthcare. This Gimli page shows the latest available BROOKS price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹64.56
1W return
+8.10%
1M return
+17.81%
3M return
+5.39%
6M return
+15.33%
1Y return
-42.33%
Market cap
₹190.18 cr
PE
14.40
PB
1.55
ROE
+11.97%
ROCE
+11.78%
RSI
53.96
Turnover
₹0.43 cr
Why it can matter in screens
- Momentum: BROOKS is above 50DMA, above 200DMA; RSI is 53.96.
- Returns: 1D +1.73%, 1W +8.10%, 1M +17.81%, 3M +5.39%, 1Y -42.33%.
- Trend levels: 52W high ₹79.69, 52W low ₹52.97, off high -18.99%.
- Liquidity: latest turnover is ₹0.43 cr; volume vs 20D is +0.30%.
- Valuation/profitability: PE 14.40, PB 1.55, ROE +11.97%, ROCE +11.78%.
- Growth: 3Y sales CAGR +11.12%, 3Y profit CAGR n/a.
Quick Answers
Is BROOKS above its 50DMA and 200DMA?
BROOKS is above 50DMA, above 200DMA. The latest 50DMA is 62.51 and the latest 200DMA is 63.29.
What are BROOKS PE, ROE and ROCE?
BROOKS has PE 14.40, ROE +11.97%, and ROCE +11.78% in Gimli's latest available snapshot.
How has BROOKS performed recently?
BROOKS has returned +17.81% over 1 month, +5.39% over 3 months, and -42.33% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 22.96 cr | -1.17 cr | -1.79 cr | -0.61 |
| 2026-03-31 | 20.21 cr | 2.02 cr | 1.52 cr | 0.52 |
| 2025-12-31 | 16.57 cr | 6.05 cr | 5.50 cr | 1.87 |
| 2025-09-30 | 23.45 cr | 8.65 cr | 7.98 cr | 2.71 |
| 2025-06-30 | 25.51 cr | 10.28 cr | 9.58 cr | 3.25 |
| 2025-03-31 | 23.32 cr | -0.63 cr | -1.46 cr | -0.54 |
| 2024-12-31 | 20.52 cr | -1.46 cr | n/a | nan |
| 2024-09-30 | 20.79 cr | -3.21 cr | n/a | -1.51 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 85.74 cr | 27.01 cr | 24.58 cr | 8.35 |
| 2025-03-31 | 82.56 cr | -7.16 cr | -9.97 cr | -3.72 |
| 2024-03-31 | 79.01 cr | -17.07 cr | -19.59 cr | -7.67 |
| 2023-03-31 | 62.48 cr | -29.39 cr | -20.89 cr | -12.57 |
| 2022-03-31 | 77.91 cr | -13.72 cr | 0.67 cr | 0.27 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 148.17 cr | 6.59 cr | 8.52 cr | 122.66 cr |
| 2025-03-31 | 123.69 cr | 0.04 cr | 7.58 cr | 98.10 cr |
| 2024-03-31 | 90.45 cr | 0.13 cr | 5.64 cr | 65.59 cr |
| 2023-03-31 | 109.60 cr | 0.02 cr | 6.51 cr | 73.95 cr |
| 2022-03-31 | 195.91 cr | 2.60 cr | 25.26 cr | 134.32 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 9.29 cr | 5.79 cr | n/a |
| 2025-03-31 | 2.63 cr | 1.70 cr | n/a |
| 2024-03-31 | -9.80 cr | -10.24 cr | n/a |
| 2023-03-31 | -14.49 cr | -14.96 cr | n/a |
| 2022-03-31 | -37.44 cr | -60.66 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +52.62% | +0.00% | +10.38% | +9.90% | +37.00% | +0.00% |
| 2026-03-31 | +52.62% | +0.17% | +10.38% | +9.90% | +36.84% | +0.00% |
| 2025-12-31 | +52.62% | +0.09% | +10.38% | +9.90% | +36.91% | +0.00% |
| 2025-09-30 | +52.62% | +0.01% | +10.38% | +9.90% | +37.00% | +0.00% |
| 2025-06-30 | +52.62% | +0.00% | +10.38% | +9.90% | +37.00% | +0.00% |
| 2025-03-31 | +52.62% | +0.05% | +10.38% | +9.90% | +36.95% | +0.00% |
| 2025-01-29 | +52.62% | +0.00% | +9.90% | +9.90% | +37.48% | +0.00% |
| 2024-12-31 | +59.06% | +0.01% | +3.86% | +3.86% | +37.08% | +0.00% |
| 2024-09-30 | +63.59% | +0.02% | +3.86% | +3.86% | +32.53% | +0.00% |
| 2024-06-30 | +63.59% | +0.00% | +3.86% | +3.86% | +32.55% | +0.00% |
| 2024-03-31 | +63.59% | +0.00% | +3.86% | +3.86% | +32.55% | +0.00% |
| 2023-12-31 | +63.59% | +0.00% | +3.86% | +3.86% | +32.55% | +0.00% |
| 2023-09-30 | +63.59% | +0.00% | +2.46% | +2.46% | +33.94% | +0.00% |
| 2023-08-28 | +63.59% | +0.00% | +1.25% | +1.25% | +35.16% | +0.00% |
| 2023-06-30 | +66.41% | +0.00% | +0.00% | +0.00% | +33.59% | +0.00% |
| 2023-03-31 | +66.41% | +0.00% | +0.06% | +0.00% | +33.52% | +0.00% |
| 2022-12-31 | +66.41% | +0.00% | +0.06% | +0.00% | +33.52% | +0.00% |
| 2022-09-30 | +66.41% | +0.00% | +0.00% | +0.00% | +33.59% | +0.00% |
| 2022-06-30 | +66.41% | +0.00% | +0.00% | n/a | n/a | +0.00% |
| 2022-03-31 | +66.41% | +0.00% | +0.00% | n/a | n/a | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 424,658.30 cr | 35.053345 | +15.50% | +3.72% |
| DIVISLAB | DIVI S LABORATORIES LTD | 267,167.60 cr | 91.684145 | +18.37% | +47.91% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 157,377.11 cr | 74.094685 | +16.87% | +28.16% |
| LAURUSLABS | LAURUS LABS LIMITED | 125,408.69 cr | 114.827348 | +21.77% | +138.16% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 124,833.39 cr | 27.818646 | +16.04% | +26.46% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 121,354.29 cr | 57.614911 | +22.62% | +7.87% |
| DRREDDY | DR. REDDY S LABORATORIES | 113,923.95 cr | 40.698752 | +7.80% | +14.41% |
| CIPLA | CIPLA LTD | 112,841.65 cr | 38.950805 | +8.80% | -7.58% |
Try these prompts
- Analyze BROOKS LAB with valuation, momentum and industry peers
- Compare BROOKS with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare BROOKS with other Healthcare stocks
Data snapshot: 2026-11-03. Not investment advice.